They naturally shorten over time and are therefore involved in many biological ... such as Dyskeratosis Congenita, bone ...

ACCESS aims to enroll approximately 220 adults living with obesity, or overweight with a weight-related comorbidity, and is designed to evaluate doses up to 120 mg and optimize titration regimens of ...

Everyone has a "family" of internal parts that aim to protect and govern behaviors and emotions. What happens when this ...

Professor Nancy Ip discusses her groundbreaking neuroscience research, focusing on neurotrophic factors and innovative ...

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...

Survival rates for idiopathic pulmonary fibrosis are worse than all solid cancers except for lung and pancreatic cancer. | ...

As physicians we take an oath to do no harm, yet are trapped providing care in a system that leaves patients confined and at ...

A new computational method can identify how cause-and-effect relationships ebb and flow over time in dynamic real-life systems such as the brain.

Calendar-year inflation forecasts from Federal Open Market Committee meeting participants typically start near 2% and then ...

The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...